Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Biochemistry & Molecular Biology
Zhen Cui et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly worldwide due to its increased fitness, with spike structures that maintain stability for receptor recognition but compromise viral fusion efficiency. By altering amino acids and structures, it evades recognition by most antibodies, facilitating immune escape. The research sheds light on conserved regions for the development of broad-spectrum vaccines.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.
Letter
Immunology
Celine Boschi et al.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Bo Meng et al.
Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Kang Wang et al.
Summary: The Omicron variant of SARS-CoV-2 is highly resistant to neutralizing antibodies, which raises concerns about the effectiveness of antibody therapies and vaccines. A study found that individuals who received two or three doses of an inactivated SARS-CoV-2 vaccine had varying rates of seroconversion for neutralizing antibodies. The effectiveness of neutralizing antibodies against Omicron was significantly lower in individuals who received three vaccine doses. However, monoclonal antibodies derived from individuals who received three vaccine doses showed strong neutralizing activity against all variants of concern, including Omicron.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Biochemistry & Molecular Biology
Laura A. VanBlargan et al.
Summary: The emergence of the B.1.1.529 Omicron variant raises concerns about the efficacy of antibody countermeasures. This study shows that some of the antibodies currently in clinical use may lose their ability to neutralize the Omicron variant.
Article
Biochemistry & Molecular Biology
Henning Gruell et al.
Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.
Letter
Medicine, General & Internal
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Xun Wang et al.
Summary: This study found that the Omicron variant is highly resistant to neutralization by sera from convalescents or individuals vaccinated with two doses of inactivated whole-virion vaccines. However, a homologous or heterologous booster significantly increased neutralization titers. Additionally, the Omicron variant resists most monoclonal antibodies targeting distinct epitopes. These findings highlight the importance of pushing forward booster vaccinations to combat emerging SARS-CoV-2 variants.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Multidisciplinary Sciences
Pavlo Gilchuk et al.
Summary: The COVID-19 pandemic has highlighted the urgent need for rapid evaluation of neutralizing antibody responses and the development of antibody-based treatments. The currently approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. This study presents a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Additionally, the researchers introduce a neutralizing antibody standard reagent to calibrate antibody neutralizing activity in convalescent plasma.
Editorial Material
Infectious Diseases
Feng Zhu et al.
Article
Immunology
Sebastian R. Schulz et al.
Summary: In this study, the efficacy of boost immunization with BNT162b2 and therapeutic antibodies in neutralizing the Omicron variant was determined using flow cytometry-based assays. The results showed that a third vaccination with BNT162b2 increased the amount of neutralizing antibodies against the Omicron variant, although to a lesser degree compared to the parental strain. Additionally, most clinically approved therapeutic antibodies failed to recognize and neutralize the Omicron variant, while some antibodies under preclinical development showed potential in neutralizing it.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Infectious Diseases
Daniel J. Sheward et al.
Summary: This study highlights the extensive but incomplete evasion of neutralizing antibody responses by the omicron variant, and suggests that boosting with licensed vaccines might be sufficient to raise neutralizing antibody levels to protective levels.
LANCET INFECTIOUS DISEASES
(2022)
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Timothee Bruel et al.
Summary: There are differences in neutralizing activity of therapeutic antibodies against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, and immunocompromised individuals treated with antibodies show elevated antibody levels but reduced neutralization against Omicron. Breakthrough infections with the Omicron variant are observed in some immunocompromised individuals despite antibody treatment.
Letter
Medicine, General & Internal
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Tongqing Zhou et al.
Summary: In this study, the cryo-electron microscopy structures of the B.1.1.529 (Omicron) variant of SARS-CoV-2 were determined, and receptor binding domain (RBD) antibodies were evaluated for their ability to bind and neutralize this variant. The study found that certain monoclonal antibodies still retained substantial inhibitory activity and identified combinations of antibodies with synergistic neutralization.
Article
Cell Biology
Sabrina Lusvarghi et al.
Summary: The neutralization capacity of the Omicron variant by postvaccination serum samples was found to be low, but increased significantly after a booster vaccination. Among the therapeutic antibody products tested, only a few showed high potency against Omicron. These findings highlight the importance of mRNA vaccine boosters and the need for the rapid development of antibody therapeutics to combat emerging variants.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Franck Touret et al.
Summary: The Omicron variant of SARS-CoV-2 has compromised the efficacy of current vaccines and therapeutic antibodies, with six out of eight antibodies losing their ability to neutralize the variant. Rapid evaluation of initial proposed doses and considering modification of doses or combination therapies may be necessary.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Takuya Tada et al.
Summary: This study found that the Omicron variant has significantly reduced sensitivity to neutralization by vaccines and vaccine-elicited antibodies. However, a booster immunization can enhance the neutralizing effect against Omicron. In addition, individuals with a history of prior SARS-CoV-2 infection showed increased neutralizing activity against Omicron. Different monoclonal antibodies showed varying effectiveness against the Omicron variant.
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Letter
Cell Biology
Bin Ju et al.
Article
Biochemistry & Molecular Biology
Meng Yuan et al.
Summary: Since the outbreak of COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have collaborated to study the novel pandemic virus SARS-CoV-2. The focus has been on the antibody response to SARS-CoV-2, crucial for vaccine and therapeutic development. Most of the neutralizing antibodies for SARS-CoV-2 target the spike protein receptor binding domain (RBD).
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Microbiology
Drew Weissman et al.
Summary: The D614G mutation in the spike protein of SARS-CoV-2 is not expected to hinder current vaccine development, as viruses with the G614 spike are more susceptible to neutralization, indicating that the mutation may not affect vaccine efficacy.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: Antibodies play a crucial role in immune protection against SARS-CoV-2, with some being used as therapeutics. A study identified 377 human monoclonal antibodies, focusing on 80 that bind the virus spike, and found that most highly inhibitory antibodies can block the virus-receptor interaction. Novel binding modes of potent inhibitory antibodies were discovered, showing potential for prophylactic or therapeutic use in animal models.
Article
Multidisciplinary Sciences
Yunda Huang et al.
Summary: The study compares two different neutralizing antibody assays used in COVID-19 vaccine efficacy trials and demonstrates that calibration approaches can be used to align the results from the two assays onto a common scale. This may assist in decision-making for evaluating and licensing new or adapted COVID-19 vaccines based on data from these assays.
SCIENTIFIC REPORTS
(2021)
Review
Medicine, General & Internal
Matthew J. Page et al.
Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Multidisciplinary Sciences
Florian A. Lempp et al.
Summary: The study reveals that C-type lectin receptors and other factors can serve as attachment receptors for SARS-CoV-2 infection, enhancing ACE2-mediated infection and modulating the neutralizing activity of antibodies.
Article
Microbiology
Jinhui Dong et al.
Summary: Structural analysis of two human monoclonal antibodies forming the antibody cocktail AZD7442, when bound to the RBD of SARS-CoV-2, demonstrates strong neutralization of variants of concern. Genetic and structural basis of neutralization has been defined, revealing crucial binding residues and positions of concern for virus escape. These germ line-encoded antibody features enable recognition of SARS-CoV-2 spike RBD and showcase the utility of cocktail AZD7442 in neutralizing emerging variant viruses.
NATURE MICROBIOLOGY
(2021)
Article
Cell Biology
Tyler N. Starr et al.
Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.
CELL REPORTS MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jun Lan et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Review
Immunology
David S. Khoury et al.
NATURE REVIEWS IMMUNOLOGY
(2020)
